Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunomodulators (Lenalidomide and Adenosylmethionine) for HIV Reservoir Reduction
NCT05598580Phase 4Unknown
- Sponsor
- First Affiliated Hospital, Zhejiang University School of Medicine
- Start
- Nov 2022
- Primary completion
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of lenalidomide, S-adenosylmethionine in human immunodeficiency virus infection (HIV), sponsored by First Affiliated Hospital, Zhejiang University School of Medicine. Status: unknown.
02
Drugs
lenalidomideS-adenosylmethionine
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT05598580.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05598580.